The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.

Link:
Autor/in:
Erscheinungsjahr:
2013
Medientyp:
Text
Beschreibung:
  • We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).
  • We carried out a prospective clinical study to evaluate the impact of the Recurrence Score (RS) on treatment decisions in early breast cancer (EBC).
Lizenz:
  • info:eu-repo/semantics/restrictedAccess
Quellsystem:
Forschungsinformationssystem des UKE
Interne Metadaten
Quelldatensatz
oai:pure.atira.dk:publications/a495541b-b78f-4ef4-be99-bba16a11184e